Alembic Pharmaceuticals announced on July 18, 2026, that its partner NATCO Pharma Limited has received tentative approval from the United States Food and Drug Administration (USFDA) for Olaparib Tablets, 100 mg and 150 mg. The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product Lynparza Tablets, 100 mg and 150 mg, of AstraZeneca Pharmaceuticals LP. This development allows Alembic to distribute the product in the U.S. market, while NATCO will handle the manufacturing of the tablets.

The Para IV litigation for the product is currently on-going. According to IQVIA data, Olaparib Tablets, 100 mg and 150 mg, have an estimated market size of approximately USD 1.4 billion in the U.S. for the twelve months ending March 2026. This market potential represents a significant commercial opportunity for the partnership.

Approval Details

The tentative approval covers the specific strengths of 100 mg and 150 mg. The product is indicated for the same uses as the reference listed drug. The distribution strategy involves Alembic managing the U.S. market supply chain, leveraging its established presence, while NATCO utilizes its manufacturing capabilities for production.

Regulatory Portfolio

With this latest tentative approval, Alembic has reached a cumulative total of 244 ANDA approvals from the USFDA. This portfolio consists of 224 final approvals and 20 tentative approvals. The company continues to expand its footprint in the complex generic market through such regulatory milestones.

Alembic Pharmaceuticals has disclosed that the United States Food and Drug Administration (USFDA) issued a Warning Letter to a Clinical Investigator associated with a bioequivalence study conducted at its Vadodara facility. The letter, dated July 10, 2026, pertains to observations regarding the Informed Consent Form (ICF) used during the study. The company clarified that these observations do not relate to data integrity issues, and no restrictions have been imposed on the operations of its Bioequivalence Facility.

The USFDA inspection that led to this correspondence was conducted between March 3, 2025, and March 7, 2025. Alembic Pharmaceuticals became aware of the Warning Letter on July 12, 2026. Based on a preliminary assessment, the company stated that the regulatory action does not impose any material financial impact or operational restrictions on its Bioequivalence Facility.

Regulatory Disclosure Details

The company submitted the necessary details to the stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The following table summarizes the key information regarding the USFDA communication:

Alembic Pharmaceuticals is currently coordinating with the Clinical Investigator to submit an appropriate response to the USFDA within the stipulated timeline. The company stated that it is evaluating the matter further.